AASLD GUIDELINES Bundle (free trial)

AASLD Hepatitis C

AASLD GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/53004

Contents of this Issue

Navigation

Page 17 of 17

Sources Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-1444. (This practice guideline was approved by the AASLD and endorsed by the Infectious Diseases Society of America, American College of Gastroenterology, and the National Viral Hepatitis Roundtable.) Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374. (This document [the original article] was approved by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology.) Abbreviations AASLD, American Association for the Study of Liver Diseases; ANC, absolute neutrophil count; anti-HCV, antibody to HCV; CHC, chronic hepatitis C; ClCr CTP, Child-Turcotte-Pugh; D/C, discontinue; EIA, enzyme immunoassay; ETR, end- of-treatment response; EVR, early virological response; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; PCR, polymerase chain reaction; PegIFN, peginterferon; PI, protease inhibitor; RBV, ribavirin; RVR, rapid virological response; Rx, treatment; SVR, sustained virological response , creatinine clearance Disclaimer This Guideline attempts to define principles of practice that should produce high-quality patient care. It focuses on the needs of primary care practice but also is applicable to providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aſter consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. HEP101121 5740 Executive Drive Suite 218 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2012 All rights reserved

Articles in this issue

Links on this page

Archives of this issue

view archives of AASLD GUIDELINES Bundle (free trial) - AASLD Hepatitis C